AHR and nonpapillary renal cell carcinoma: In this work, we investigated the canonical response to TCDD mediated by the aryl hydrocarbon receptor (AHR) and the expression of its interactors, comparing exposure to the receptor’s most potent ligand with the ccRCC pathology condition that precludes the main interaction with the ARNT/HIF1B.